

**NATIONAL INSTITUTE FOR HEALTH AND CARE  
EXCELLENCE**

**HEALTH TECHNOLOGY APPRAISAL PROGRAMME**

**Equality impact assessment – Guidance development**

**STA Fedratinib for treating disease-related splenomegaly  
or symptoms in myelofibrosis (Review of TA756)**

The impact on equality has been assessed during this appraisal according to the principles of the NICE equality scheme.

**Final draft guidance**

|  |
|--|
| 1. Have any additional potential equality issues been raised during the consultation, and, if so, how has the committee addressed these? |
| None identified  |

|  |
|--|
| 2. If the recommendations have changed after consultation, are there any recommendations that make it more difficult in practice for a specific group to access the technology compared with other groups? If so, what are the barriers to, or difficulties with, access for the specific group? |
| No   |

|   |
|---|
| 3. If the recommendations have changed after consultation, is there potential for the recommendations to have an adverse impact on people with disabilities because of something that is a consequence of the disability? |
| No  |

|  |
|--|
| 4. If the recommendations have changed after consultation, are there any recommendations or explanations that the committee could make to remove or alleviate barriers to, or difficulties with, access identified in questions 2 and 3, or otherwise fulfil NICE's obligations to promote equality? |
| No   |

|  |
|--|
| 5. Have the committee's considerations of equality issues been described in the final draft guidance, and, if so, where? |
| Yes, see section 3.21.   |

**Approved by Associate Director (name):** Ross Dent

**Date:** 01/10/2024